tiprankstipranks
Trending News
More News >
Radiopharm Theranostics Limited (AU:RAD)
ASX:RAD
Australian Market

Radiopharm Theranostics Limited (RAD) AI Stock Analysis

Compare
18 Followers

Top Page

AU

Radiopharm Theranostics Limited

(Sydney:RAD)

Rating:34Underperform
Price Target:
Radiopharm Theranostics Limited is struggling with typical challenges faced by emerging biotech firms. The financial performance is constrained by significant losses and cash flow issues, despite a debt-free balance sheet. Technical analysis shows a bearish trend with potential for a short-term rebound. Valuation metrics highlight the speculative nature of the investment due to ongoing financial challenges and lack of profitability.
Positive Factors
Clinical Trials
The advancement of RAD 204 into a first-in-human Phase I trial in non-small cell lung cancer is a significant development for Radiopharm Theranostics.
Strategic Focus
Radiopharm Theranostics focuses its therapeutic pipeline on biologically validated targets that have limited use in radiopharmaceuticals, reducing development risk and competition.
Negative Factors
Capital Raise
The AUD 70M capital raise resulted in higher dilution than previously estimated due to associated lower prices.

Radiopharm Theranostics Limited (RAD) vs. iShares MSCI Australia ETF (EWA)

Radiopharm Theranostics Limited Business Overview & Revenue Model

Company DescriptionRadiopharm Theranostics Limited (RAD) is a biotechnology company focused on the development and commercialization of radiopharmaceutical products for both diagnostic and therapeutic use in the field of oncology. The company leverages advanced medical imaging and targeted radiotherapy technologies to create innovative solutions that improve cancer diagnosis and treatment outcomes. By integrating theranostics, which combines therapeutic and diagnostic capabilities, Radiopharm aims to enhance the precision and effectiveness of cancer care.
How the Company Makes MoneyRadiopharm Theranostics Limited generates revenue primarily through the development, licensing, and commercialization of its radiopharmaceutical products. The company's revenue streams include sales of diagnostic and therapeutic radiopharmaceuticals, milestone payments, and royalties from licensing agreements with pharmaceutical and biotechnology companies. Additionally, Radiopharm may enter into strategic partnerships to co-develop products, sharing both the costs and revenues. The company also invests in research and development to expand its product pipeline, aiming to introduce new and innovative solutions to the market, thereby increasing its revenue potential.

Radiopharm Theranostics Limited Financial Statement Overview

Summary
Radiopharm Theranostics Limited faces significant financial challenges typical of early-stage biotech firms. The income statement shows negative profit margins and increasing losses despite slight revenue growth. The balance sheet is moderately strong with no debt but is weakened by substantial net losses and high liabilities. Cash flow is negative, indicating significant cash outflows and a high burn rate, which necessitate continued external financing.
Income Statement
20
Very Negative
Radiopharm Theranostics Limited shows significant challenges in profitability. The gross profit margin and net profit margin are negative due to high costs and low revenue generation. There is a slight revenue growth from the previous year, but it is overshadowed by increasing losses. Overall, the income statement reflects ongoing financial struggles typical in the biotechnology industry, which often faces long R&D phases before profitability.
Balance Sheet
35
Negative
The company's balance sheet reveals a moderate equity position with no debt, which is a positive factor. However, the return on equity is negative due to substantial net losses. The equity ratio indicates a reliance on equity financing, common for early-stage biotech firms. The financial stability is challenged by declining equity and high liabilities, which are concerning for future financial health.
Cash Flow
25
Negative
Radiopharm Theranostics is experiencing negative operating and free cash flows, indicating cash outflow challenges. The company's ability to convert net income to cash flow is poor, as seen in the negative cash flow to net income ratios. Despite some financing inflows, the high cash burn rate is a significant risk, underscoring the need for continued external financing.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021
Income StatementTotal Revenue
1.38M299.23K292.36K8.83K0.00
Gross Profit
-17.08M-21.31M-3.00M-2.97M0.00
EBIT
-38.90M-36.62M-40.29M-23.93M-484.75K
EBITDA
-36.53M-45.38M-31.19M-18.04M-484.75K
Net Income Common Stockholders
-41.92M-47.95M-34.61M-30.34M-485.19K
Balance SheetCash, Cash Equivalents and Short-Term Investments
32.59M18.58M11.70M26.98M27.09K
Total Assets
91.05M72.04M74.95M83.38M33.44K
Total Debt
0.000.000.000.0059.00K
Net Debt
-32.59M-18.58M-11.70M-26.98M31.91K
Total Liabilities
17.63M44.68M29.37M20.42M158.14K
Stockholders Equity
73.42M28.12M44.38M62.96M-124.70K
Cash FlowFree Cash Flow
-33.42M-22.98M-24.73M-38.25M-32.91K
Operating Cash Flow
-33.42M-22.98M-23.20M-9.91M-32.91K
Investing Cash Flow
3.00M0.00-1.53M-28.37M0.00
Financing Cash Flow
64.51M29.88M9.22M65.11M60.00K

Radiopharm Theranostics Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.02
Price Trends
50DMA
0.02
Negative
100DMA
0.02
Negative
200DMA
0.03
Negative
Market Momentum
MACD
<0.01
Negative
RSI
42.00
Neutral
STOCH
4.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RAD, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 42.00 is Neutral, neither overbought nor oversold. The STOCH value of 4.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:RAD.

Radiopharm Theranostics Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AURAC
54
Neutral
AU$205.88M-37.20%32.02%
54
Neutral
$5.37B3.35-45.10%2.79%16.77%-0.01%
AUPYC
53
Neutral
AU$699.91M-112.97%-84.82%
AUIMU
41
Neutral
$119.47M-99.05%-34.09%
AUBIT
36
Underperform
AU$3.32M-119.28%64.10%
AURAD
34
Underperform
AU$58.35M-108.26%53.41%
AUOPT
30
Underperform
$738.77M
-24.46%-7.90%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:RAD
Radiopharm Theranostics Limited
0.02
>-0.01
-33.33%
AU:OPT
Opthea
0.60
0.15
34.53%
AU:BIT
Biotron
0.01
-0.04
-78.00%
AU:IMU
Imugene Limited
0.02
-0.04
-72.41%
AU:PYC
PYC Therapeutics Limited
1.20
0.16
15.38%
AU:RAC
Race Oncology Ltd.
1.17
-0.73
-38.42%

Radiopharm Theranostics Limited Corporate Events

Radiopharm Theranostics Advances in Clinical Trials and Secures Major Investment
Apr 29, 2025

Radiopharm Theranostics Limited announced significant advancements in its clinical trials and shareholder structure. Lantheus Holdings Inc. increased its stake to 12.16% through a US$5 million placement, providing funds to advance Radiopharm’s clinical pipeline. The company reported successful detection of brain metastases using RAD 101, a novel imaging agent, and positive preclinical data for RAD202, a HER2-targeting radiopharmaceutical. These developments underscore Radiopharm’s potential to improve cancer diagnostics and treatment, positioning it as a key player in the radiopharmaceutical industry.

Radiopharm Theranostics Initiates U.S. Phase 2b Imaging Study for Brain Metastasis
Apr 28, 2025

Radiopharm Theranostics has commenced dosing the first patient in a U.S. Phase 2b imaging study using 18F-RAD101 for suspected recurrent brain metastasis. This trial aims to evaluate the diagnostic performance of 18F-RAD101, a novel imaging small molecule targeting fatty acid synthase, in patients with confirmed recurrent brain metastases. The study’s primary objective is to assess the concordance between 18F-RAD101 positive lesions and conventional MRI imaging. The trial underscores Radiopharm’s commitment to advancing diagnostic precision in oncology, potentially improving treatment decisions for over 300,000 patients diagnosed with brain metastasis annually in the U.S.

Radiopharm Theranostics Reports Positive Data on RAD202 for HER2-Positive Tumors
Mar 17, 2025

Radiopharm Theranostics Limited has announced positive data from studies on its RAD202 product, presented at the European Molecular Imaging Meeting 2025. The data highlights the specific tumor targeting and favorable biodistribution of 68Ga-RAD202 for imaging, and the efficacy of 177Lu-RAD202 in reducing tumor volume and extending survival in HER2-positive solid tumors. These findings support ongoing clinical trials and suggest potential benefits for patients with advanced HER2-positive cancers, positioning the company as a leader in addressing unmet needs in oncology.

Radiopharm Theranostics Reports Reduced Losses for H2 2024
Feb 28, 2025

Radiopharm Theranostics Limited reported a 20.90% decrease in its loss from ordinary activities after tax for the half-year ended December 31, 2024, amounting to $18,725,453. Despite the reduction in losses, the company did not declare any dividends for the current or previous financial periods, and there were no changes in controlled entities. The financial statements were reviewed by an independent auditor, who issued an unmodified opinion, reflecting stability in the company’s financial reporting.

Radiopharm Theranostics to Present at TD Cowen Healthcare Conference
Feb 24, 2025

Radiopharm Theranostics Limited announced its participation in the TD Cowen Annual Healthcare Conference in Boston, where CEO Riccardo Canevari will present the company’s investment proposition. This presentation is a strategic move to attract investor interest, showcasing Radiopharm’s world-class pipeline and potential market leadership in radiopharmaceuticals, particularly in areas with high unmet medical needs.

Radiopharm Theranostics to Present at B. Riley Precision Oncology Conference
Feb 17, 2025

Radiopharm Theranostics Limited announced its participation in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York on 28 February 2025. This event will feature over 35 biopharma and med-tech companies, providing Radiopharm an opportunity to present its innovative oncology solutions to a mix of institutional and professional investors, potentially enhancing its industry positioning and stakeholder engagement.

Radiopharm Theranostics Unveils Successful Detection of Brain Metastases with RAD 101
Feb 9, 2025

Radiopharm Theranostics Limited has announced successful clinical trial data showcasing the effectiveness of RAD 101 (18F-Pivalate) in detecting brain metastases using a novel PET-mpMRI imaging approach. This breakthrough demonstrates a high tumor-to-background ratio, promising a more sensitive detection method compared to the current standard of care, and could significantly improve diagnostic accuracy for suspected recurrent brain metastases. The ongoing Phase 2b trial in the United States aims to further evaluate the diagnostic performance of RAD 101, potentially enhancing the company’s positioning in the oncology radiopharmaceutical market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.